BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 24958556)

  • 1. Ultrasound-planned high-dose-rate prostate brachytherapy: dose painting to the dominant intraprostatic lesion.
    Crook J; Ots A; Gaztañaga M; Schmid M; Araujo C; Hilts M; Batchelar D; Parker B; Bachand F; Milette MP
    Brachytherapy; 2014; 13(5):433-41. PubMed ID: 24958556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose to the dominant intraprostatic lesion using HDR vs. LDR monotherapy: A Phase II randomized trial.
    Tissaverasinghe S; Crook J; Bachand F; Batchelar D; Hilts M; Araujo C; Anderson D; Bainbridge T; Farnquist B
    Brachytherapy; 2019; 18(3):299-305. PubMed ID: 30795889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inverse planning for HDR prostate brachytherapy used to boost dominant intraprostatic lesions defined by magnetic resonance spectroscopy imaging.
    Pouliot J; Kim Y; Lessard E; Hsu IC; Vigneron DB; Kurhanewicz J
    Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):1196-207. PubMed ID: 15234056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose escalation to dominant intraprostatic lesions with MRI-transrectal ultrasound fusion High-Dose-Rate prostate brachytherapy. Prospective phase II trial.
    Gomez-Iturriaga A; Casquero F; Urresola A; Ezquerro A; Lopez JI; Espinosa JM; Minguez P; Llarena R; Irasarri A; Bilbao P; Crook J
    Radiother Oncol; 2016 Apr; 119(1):91-6. PubMed ID: 26900090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conformal prostate brachytherapy: initial experience of a phase I/II dose-escalating trial.
    Martinez A; Gonzalez J; Stromberg J; Edmundson G; Plunkett M; Gustafson G; Brown D; Yan D; Vicini F; Brabbins D
    Int J Radiat Oncol Biol Phys; 1995 Dec; 33(5):1019-27. PubMed ID: 7493828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dosimetric evaluation of MRI-to-ultrasound automated image registration algorithms for prostate brachytherapy.
    Shaaer A; Paudel M; Davidson M; Semple M; Nicolae A; Mendez LC; Chung H; Loblaw A; Tseng CL; Morton G; Ravi A
    Brachytherapy; 2020; 19(5):599-606. PubMed ID: 32712028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results of multiparametric transrectal ultrasound-based focal high-dose-rate dose escalation combined with supplementary external beam irradiation in intermediate- and high-risk localized prostate cancer patients.
    Kovács G; Müller K; Soror T; Melchert C; Guo X; Jocham D; Merseburger A
    Brachytherapy; 2017; 16(2):277-281. PubMed ID: 27964906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Image-guided high-dose-rate brachytherapy boost to the dominant intraprostatic lesion using multiparametric magnetic resonance imaging including spectroscopy: Results of a prospective study.
    Vigneault E; Mbodji K; Racine LG; Chevrette E; Lavallée MC; Martin AG; Després P; Beaulieu L
    Brachytherapy; 2016; 15(6):746-751. PubMed ID: 27743955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IMRT boost dose planning on dominant intraprostatic lesions: gold marker-based three-dimensional fusion of CT with dynamic contrast-enhanced and 1H-spectroscopic MRI.
    van Lin EN; Fütterer JJ; Heijmink SW; van der Vight LP; Hoffmann AL; van Kollenburg P; Huisman HJ; Scheenen TW; Witjes JA; Leer JW; Barentsz JO; Visser AG
    Int J Radiat Oncol Biol Phys; 2006 May; 65(1):291-303. PubMed ID: 16618584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Feasibility of dominant intraprostatic lesion boosting using advanced photon-, proton- or brachytherapy.
    Andrzejewski P; Kuess P; Knäusl B; Pinker K; Georg P; Knoth J; Berger D; Kirisits C; Goldner G; Helbich T; Pötter R; Georg D
    Radiother Oncol; 2015 Dec; 117(3):509-14. PubMed ID: 26349588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiparametric MRI-guided dose boost to dominant intraprostatic lesions in CT-based High-dose-rate prostate brachytherapy.
    Wang T; Press RH; Giles M; Jani AB; Rossi P; Lei Y; Curran WJ; Patel P; Liu T; Yang X
    Br J Radiol; 2019 May; 92(1097):20190089. PubMed ID: 30912959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 3-D conformal HDR brachytherapy as monotherapy for localized prostate cancer. A pilot study.
    Martin T; Baltas D; Kurek R; Röddiger S; Kontova M; Anagnostopoulos G; Dannenberg T; Buhleier T; Skazikis G; Tunn U; Zamboglou N
    Strahlenther Onkol; 2004 Apr; 180(4):225-32. PubMed ID: 15057433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose-rate prostate brachytherapy consistently results in high quality dosimetry.
    White EC; Kamrava MR; Demarco J; Park SJ; Wang PC; Kayode O; Steinberg ML; Demanes DJ
    Int J Radiat Oncol Biol Phys; 2013 Feb; 85(2):543-8. PubMed ID: 22652111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate stereotactic ablative radiation therapy using volumetric modulated arc therapy to dominant intraprostatic lesions.
    Murray LJ; Lilley J; Thompson CM; Cosgrove V; Mason J; Sykes J; Franks K; Sebag-Montefiore D; Henry AM
    Int J Radiat Oncol Biol Phys; 2014 Jun; 89(2):406-15. PubMed ID: 24685447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Virtual HDR CyberKnife treatment for localized prostatic carcinoma: dosimetry comparison with HDR brachytherapy and preliminary clinical observations.
    Fuller DB; Naitoh J; Lee C; Hardy S; Jin H
    Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1588-97. PubMed ID: 18374232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dominant intraprostatic lesion boosting in sexual-sparing radiotherapy of prostate cancer: A planning feasibility study.
    Ciabatti S; Ntreta M; Buwenge M; Gaudiano C; Sessagesimi E; Romani F; Angelini AL; Cammelli S; Macchia G; Deodato F; Zamagni A; Golfieri R; Morganti AG; Cilla S
    Med Dosim; 2019 Winter; 44(4):356-364. PubMed ID: 30955990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dosimetric impact of interfraction catheter movement in high-dose rate prostate brachytherapy.
    Foster W; Cunha JA; Hsu IC; Weinberg V; Krishnamurthy D; Pouliot J
    Int J Radiat Oncol Biol Phys; 2011 May; 80(1):85-90. PubMed ID: 20605353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate seed implantation using 3D-computer assisted intraoperative planning vs. a standard look-up nomogram: Improved target conformality with reduction in urethral and rectal wall dose.
    Raben A; Chen H; Grebler A; Geltzeiler J; Geltzeiler M; Keselman I; Litvin S; Sim S; Hanlon A; Yang J
    Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1631-8. PubMed ID: 15590195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dosimetry Modeling for Focal Low-Dose-Rate Prostate Brachytherapy.
    Al-Qaisieh B; Mason J; Bownes P; Henry A; Dickinson L; Ahmed HU; Emberton M; Langley S
    Int J Radiat Oncol Biol Phys; 2015 Jul; 92(4):787-93. PubMed ID: 25936808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.